A 7-Day Winning Streak Has Boston Scientific Stock Up 8.6%
A recent run in Boston Scientific has caught attention, but the underlying numbers tell their own story about the business.
Boston Scientific (BSX) stock has now moved higher for 7 consecutive trading days, producing a cumulative gain of 8.6%. That streak has added about $6.0 billion to the company’s market value. For investors holding the shares, this recent performance marks a sharp positive turn.
How The Streak Stacks Up Against The S&P 500
Here is how BSX stock stacks up against the S&P 500 over the streak and the periods around it:
- How Much More Can Boston Scientific Stock Move After Losing Half Its Value?
- Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company
- Same Industry, Less Money: What Boston Scientific and ResMed Offer That Abbott Laboratories Does Not
- Why BSX Stock Hands You So Much Cash Right Now
- The Wide Chasm Priced Into Boston Scientific Stock
- How To Target A 10% Yield While Catching The BSX Stock Knife?
| Return Period | BSX | S&P 500 |
|---|---|---|
| 1D | 0.3% | -0.2% |
| 7D (Current Streak) | 8.6% | 0.8% |
| 1M (21D) | 16.2% | 3.3% |
| 3M (63D) | -3.2% | 3.8% |
| YTD 2026 | -45.6% | 13.7% |
| 2025 | 6.8% | 16.4% |
| 2024 | 54.5% | 23.3% |
| 2023 | 24.9% | 24.2% |
Do the fundamentals support this run?
The data suggests the market is weighing more than just momentum. The move appears to be the stock’s own story, as the S&P 500 returned just +0.8% over the same period. The company’s revenue grew 13.5% over the last twelve months, ahead of the S&P 500 median revenue growth of 8.3%.
Its operating margin of 21.0% also exceeds the index median of 18.4%. The stock trades at a price-to-earnings multiple of 20.7, below the S&P 500 median of 23.8. Such streaks are relatively rare in the current market: only 4 S&P 500 stocks are currently on winning streaks of 7 days or more.
A streak is information, not an instruction.
An extended run of gains or losses is a signal of focused market attention. It is not, by itself, a reason to buy or sell. The disciplined response is to use the new information as a prompt to check the underlying business against its current price.
The fundamental comparisons here provide a starting point for that work. While any streak can end without warning, the recent buying reflects solid operational metrics—though it remains an early rebound against a steep 45.6% decline year-to-date.
A run like this is worth respecting, and worth testing: the momentum that lasts is usually the kind management itself is underwriting. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.
Those drawn to the strength but not the single-name risk have another route: a healthcare ETF like XLV holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
One Hot Stock Is A Story. Thirty Sound Ones Are A Strategy
A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?
The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Follow the story; invest in the strategy.